biostudies-literatureUnknown16Jing F<h4>Background</h4>Effective therapies for pulmonary fibrosis caused by coronavirus disease (COVID-19) and other etiologies are lacking. Our previous studies demonstrated that Fuzheng Huayu tablet (FZHY), a traditional Chinese medicine known for its anti-liver fibrotic properties, can improve lung function in patients with chronic obstructive pulmonary disease and attenuate bleomycin-induced pulmonary fibrosis in rats.<h4>Purpose</h4>This study aimed to evaluate the efficacy and safety of FZHY in post-COVID-19 pulmonary fibrosis.<h4>Methods</h4>A multi-center, randomized, double-blind, placebo-controlled clinical trial was conducted to evaluate the efficacy of a 24-week treatment with FZHY, combined with vitamin C and respiratory function rehabilitation, for treating pulmonary fibrosis in Frontiers in pharmacology1508276https://www.ebi.ac.uk/biostudies/studies/S-EPMC11933019biostudies-literatureFuzheng Huayu tablets for treating pulmonary fibrosis in post-COVID-19 patients: a multicenter, randomized, double-blind, placebo-controlled trial.PMC11933019Peng YHuang JKe JQiu QZhao ZWu HZhang WHuang TFeng JZhan SXing FJiang BWang WLiu CSu WJing FfalseFuzheng Huayu tablets for treating pulmonary fibrosis in post-COVID-19 patients: a multicenter, randomized, double-blind, placebo-controlled trial.<h4>Background</h4>Effective therapies for pulmonary fibrosis caused by coronavirus disease (COVID-19) and other etiologies are lacking. Our previous studies demonstrated that Fuzheng Huayu tablet (FZHY), a traditional Chinese medicine known for its anti-liver fibrotic properties, can improve lung function in patients with chronic obstructive pulmonary disease and attenuate bleomycin-induced pulmonary fibrosis in rats.<h4>Purpose</h4>This study aimed to evaluate the efficacy and safety of FZHY in post-COVID-19 pulmonary fibrosis.<h4>Methods</h4>A multi-center, randomized, double-blind, placebo-controlled clinical trial was conducted to evaluate the efficacy of a 24-week treatment with FZHY, combined with vitamin C and respiratory function rehabilitation, for treating pulmonary fibrosis in 2025-01-01T00:00:00Z20252026-04-08T19:46:58.357Z2025-07-04T03:05:47.81ZS-EPMC119330194013523710.3389/fphar.2025.1508276